Everyone is so focused on Humira's patent cliff, but they're missing the bigger picture here. AbbVie has been on a tear acquiring new assets and their pipeline, especially Skyrizi and Rinvoq, is absolutely stacked to drive future growth. Plus, that dividend has been consistently raised for years, so you can get paid to hold while the rest of the market catches on.
BUY.
AbbVie
ABBV
NYSE
IPO2012
about ABBV
AbbVie is a biopharmaceutical company focused on developing advanced treatments for immune-mediated diseases, cancer, and other serious health conditions, with its flagship product being the blockbuster drug Humira, used to treat rheumatoid arthritis and other inflammatory conditions.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $212.55 | $214.34 | $211.00 | $375.50B | 4.47M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$0.52 | 74.19 | 24.62 | 31.73% | 6.10% | 3.06% |
